BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Apeiron Biologics

Apeiron Biologics logo

Austria based
$30.500 M

APEIRON is a privately-held European biotech company based in the heart of Europe, in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies and respiratory treatments.

Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.

APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.


AI Companies (Drug Discovery)  

R&D Platform

Apeiron is targeting the cancer cell cycle with a portfolio of next generation CDK inhibitors and harnessing synthetic lethal interactions in anti-cancer drug discovery.


Clinical  |  Visit website

APEIRON is focused on developing therapies to effectively treat respiratory diseases and cancer. Our respiratory platform around ACE2 is specifically targeting COVID-19 as well as ARDS (Acute Respiratory Distress Syndrome) and ALI (Acute Lung Injury). Our immune-oncology pipeline concentrates on next-generation checkpoint inhibitor Cbl-b and novel IO targets to activate the patient’s immune system against various tumors.




No services posted yet